World Pharmaceutical Congress

June 5-6
Predicting Drug-Induced Cardiotoxicity
Targeting Alzheimer's Disease
Predictive Pre-Clinical Models in Oncology

June 6-7
Tackling Drug-Induced Idiosyncratic Hepatotoxicity
Molecular Imaging in Drug Discovery and Development
Targeting Pain with Novel Therapeutics
+ show speakers and program
Adeboye Adejare, Ph.D., Professor, Pharmaceutical Sciences, University of the Sciences, Philadelphia College of PharmacyAjay Verma, Vice President, Neurodegeneration and Translational Neurology, Biogen Idec
Andreas Jeromin, Ph.D., Banyan Biomarkers, Inc.
Andreas Jeromin, Ph.D., Director, Business Development and Analytical Service Lab, Banyan Biomarkers, Inc.
Anthony W. Bannon, Ph.D., Associate Director II, Neuroscience Drug Discovery, Global Pharmaceutical Research & Development, Abbott
Arie Regev, M.D., Hepatology Consultant and Chair, Liver and GI Safety Committee, Global Patient Safety, Eli Lilly and Company
Barbara Tate, Ph.D., Vice President, Biology, Satori Pharmaceuticals
Bernard P. Roques, Ph.D., Vice President & Scientific Director, Pharmaleads
Brad Bolon, D.V.M., Ph.D., DACVP, DABT, Veterinary Pathologist, Veterinary Biosciences; Associate Professor, Clinical, The Ohio State University
Brett A. Howell, Ph.D., Research Scientist, The Hamner - UNC Institute for Drug Safety Sciences
Brian Roche, Ph.D., Cardiovascular Safety Pharmacologist, Safety Pharmacology, Battelle Memorial Institute
Brooke VandenBrink, Scientist, Pharmacokinetics & Drug Metabolism, Amgen
C. Anthony Hunt, Ph.D., Department of Bioengineering and Therapeutic Sciences, University of California San Francisco
Cedo Bagi, M.D., Ph.D., Senior Research Fellow, Worldwide Comparative Medicine, Global Science & Technology, Pfizer Global R&D
Charlie Glaus, Ph.D., Scientist, Research Imaging Sciences, Amgen
Christopher T. Winkelmann, D.V.M., Ph.D., CT Imaging Lead, Imaging, Merck Research Laboratories
Corey R. Hopkins, Ph.D., Research Assistant Professor, Associate Director, Medicinal Chemistry, Drug Discovery Program, Vanderbilt
Corinne Augelli-Szafran, Ph.D., Director, Laboratory for Experimental Alzheimer Drugs (LEAD), Harvard Medical School, Department of Neurology Center for Neurologic Diseases Brigham and Women’s Hospital
Craig Ferris, Ph.D., Professor, Pharmaceutical Sciences, School of Pharmacy, Director, Ctr for Translational Imaging, Northeastern University
Cyril H. Benes, Ph.D., Principal Investigator and Director, Center for Molecular Therapeutics, Massachusetts General Hospital Cancer Center
Daniel Lenihan, M.D., Director, Clinical Research, Cardiovascular Medicine, Vanderbilt University
Daniele Piomelli, Ph.D., Drug Discovery and Development, Italian Institute of Technology; Department Pharmacology, University of California, Irvine
Dennis J. Selkoe, M.D., Vincent and Stella Coates Professor of Neurologic Diseases, Harvard Medical School; Co-Director, Center for Neurologic Diseases, Brigham and Women’s Hospital
Dinesh Puppala, Ph.D., Senior Scientist, Compound Safety Prediction Group, Pfizer, Inc.
Dinko Gonzalez Trotter, Ph.D., Director, Image Analysis and Physiology, Merck
Dwight German, Ph.D., Professor, Department of Psychiatry, University of Texas Southwestern Medical Center
Edward Bilsky, Ph.D., Professor, Pharmacology & Director, Center of Excellence in the Neurosciences, University of New England
Eileen R. Blasi, M.S., Senior Principal Research Scientist, Pharmacology, Global Safety Pharmacology, Pfizer Global Research & Development
Emma T. Bowden, Ph.D., Senior Scientist, MedImmune, an Astra Zeneca company
Eric Blomme, D.V.M., Ph.D., DACVP, Director, Investigative Toxicology and Pathology, Senior Research Fellow, Abbott Laboratories
Ernest Bush, Ph.D., Vice President and Research Director, Cambridge Healthtech Associates
Eugene Storozynsky, M.D., Ph.D., Assistant Professor of Medicine, Program in Heart Failure and Transplantation Division of Cardiology, University of Rochester Medical Center
Eugenia Gurevich, Ph.D., Associate Professor, Pharmacology, Vanderbilt University
Fuqiang Zhao Ph.D., Senior Research Scientist, Imaging, Merck Research Labs
Garth Whiteside, Ph.D., Director, Discovery, Purdue Pharma
Gary Gintant, Ph.D., Senior Group Leader, Department of Integrative Pharmacology, Global Pharmaceutical Research & Development, Abbott Laboratories
Gerry Kenna, Ph.D., Principal Scientist, Hepatic Target Organ Strategy Lead, Safety Assessment, Molecular Toxicology, AstraZeneca
Gizem Donmez, Ph.D., Assistant Professor, Neuroscience, Tufts University School of Medicine
Glenn Kirsch, Ph.D., Senior Director, Pharmacology and Program Management, ChanTest Corporation
Gregory Went, Ph.D., CEO & Chairman, Adamas Pharmaceuticals
Grisel Lopez, M.D., Senior Staff Clinician, National Human Genome Research Institute, Section on Molecular Neurogenetics, Medical Genetics Branch, NIH
Guillaume Normand, Investigator II, Novartis Pharmaceuticals Corporation
Gul Erdemli, M.D., Ph.D., DABT, Head, Ion Channel Group, Novartis Institutes for BioMedical Research, Inc
Guy Salama, Ph.D., Professor, Department of Medicine, University of Pittsburgh, School of Medicine
Handan He, Ph.D., Director, Pre-Clinical PK/PD, DMPK, Translational Sciences, Novartis
Han-Xun Wei, Ph.D., Senior Chemist, Laboratory for Experimental Alzheimer’s Drugs, Harvard Medical School
Harry Chobanian, Ph.D., Research Fellow, Discovery Chemistry, Merck Research Labs
Heiko Niessen, Ph.D., Translational Medicine Expert for Clinical Imaging, Translational Medicine, Boehringer Ingelheim Pharma GmbH & CO. KG
Imran Shah, Ph.D., Head, Computational Systems Biology, National Center for Computational Toxicology, U.S. Environmental Protection Agency
Ingrid D. Pardo, D.V.M., M.S., DipACVP, Senior Principal Scientist and Neuroanatomist, Toxicologic Pathology, Pfizer, Inc.
James Lynch, Ph.D., Senior Scientist III, Integrative Pharmacology, Global Pharmaceutical Research and Development, Abbott Laboratories
James O’Callaghan, Ph.D., Head, Molecular Neurotoxicology Laboratory, Health Effects Laboratory Division, CDC-NIOSH
Jasvinder K. Atwal, Ph.D., Senior Research Associate, Neuroscience, Genentech
Jim Pomonis, Ph.D., Director, Technical Development, Algos Preclinical Services
Jonathan Heyen, Ph.D., Principal Scientist, Global Safety Pharmacology, Pfizer Global Research & Development
José E. Manautou, Ph.D., Professor of Toxicology, Department of Pharmaceutical Sciences, University of Connecticut
Kelly Knopp, Ph.D., Senior Research Scientist, Neuroscience, Lilly Research Labs
Kenneth Dunn, Ph.D., Associate Professor of Medicine and Biochemistry, Indiana University
Kenneth Olive, M.D., Assistant Professor of Medicine and Pathology, Irving Cancer Research Center, Columbia University
Kuldip Dave, Ph.D., Associate Director, Research Programs, The Michael J. Fox Foundation for Parkinson’s Research
Lars Kaestner, Ph.D., Principal Investigator, Institute for Molecular Cell Biology, Saarland University
Lars Kaestner, Ph.D., Principal Investigator, Research Center for Molecular Imaging and Screening, Saarland University
Mallika Singh, Ph.D., Scientist, Department of Molecular Biology. Genentech
Marcelle Bergeron, Ph.D., Director, Neuropharmacology, Elan Pharmaceuticals
Maria Vlaming, Ph.D., Research Scientist, Pharmacokinetics and Human Studies, TNO, Netherlands Organization for Applied Scientific Research
Mary Ellen Cvijic, Ph.D., Principal Scientist, Lead Evaluation, Molecular Sciences and Candidate Optimization, Bristol-Myers Squibb Co.
Matt Silva, Ph.D., Director, Research Imaging Sciences, Amgen
Matthew Peters, Ph.D., Principal Scientist, Safety Assessment, Astrazeneca
Melinda Hollingshead , D.V.M., Ph.D., Chief, Biological Testing Branch, NCI-FCRDC Fairview
Merle G. Paule, Ph.D., Fellow, A.T.S., Director, Division of Neurotoxicology, National Center for Toxicological Research, Food and Drug Administration
Michel Wurm, M.D., Director, Drug and Business Development, Pharmaleads
Mike Milburn, Ph.D., CSO, Metabolon, Inc.
Nancy K. Pryer, Ph.D., Director, Oncology Pharmacology, Novartis Institutes for Biomedical Research
Nancy Levin, Ph.D., Director, Biology, CovX Research, Pfizer WRD
Neal Goodwin, Ph.D., Director, Research and Development, In Vivo Pharmacology Services, The Jackson Laboratory
Neil Buckholtz, Ph.D., Chief, Dementias of Aging Branch, Division of Neuroscience, National Institute on Aging
Nicholas Van Bruggen, Ph.D., Head, Biomedical Imaging, Genentech
Pankaj Oberoi, Ph.D., Director, Scientific Services and Research & Development, Meso Scale Discovery
Patricia Ganey, Ph.D., Professor, Pharmacology and Toxicology, Center for Integrative Toxicology, Michigan State University
Patrick McConville, Ph.D., CSO & COO, Molecular Imaging, Inc
Paul B. Watkins, M.D., Director, Hamner-UNC Institute for Drug Safety Sciences, Verne S. Caviness Distinguished Professor of Medicine, University of North Carolina at Chapel Hill
Paul Vancutsem, D.V.M., Ph.D., Director of Toxicology, Biogen Idec
Peter Hoffmann, M.D., Ph.D., Executive Director, Preclinical Safety and Translational Cardiovascular Advisory Team, Novartis Pharmaceuticals Corporation
Peter Hoffmann, M.D., Ph.D., Executive Director, Pre-Clinical Safety and Translational Cardiovascular Advisory Team, Novartis Pharmaceuticals Corporation
Praveen Balimane, Ph.D., Senior Research Investigator, Metabolism and Pharmacokinetics Group, Bristol-Myers Squibb Co.
Rakesh Dixit, Ph.D., DABT, Vice President, R&D, Global Head, Biologics Safety Assessment, MedImmune (AstraZeneca Global Biologics)
Richard Butt, Ph.D, Director, Research Project Leader, Pain Therapeutics, Pfizer Neusentis
Richard Miller, D.V.M., Ph.D., DipACVP, Vice President, Safety Assessment, GlaxoSmithKline, Inc.;
Robbie Robertson, Scientist I, Biomedical Imaging Group, Millennium: The Takeda Oncology Company
Robert H. Dworkin, Ph.D., Professor of Anesthesiology, Neurology, Oncology, and Psychiatry; Professor, Center for Human Experimental Therapeutics, University of Rochester School of Medicine and Dentistry; Director, Analgesic Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION), a public-private partnership with the FDA
Robert W. Mahley, M.D., Ph.D., President Emeritus, The J. David Gladstone Institutes; Professor, Pathology, Medicine, University of California, San Francisco
Roderic G. Eckenhoff, M.D., Vice Chair for Research, Austin Lamont Professor of Anesthesiology & Critical Care, Perelman School of Medicine, University of Pennsylvania
Ross Cagan, Ph.D., Professor, Developmental & Regenerative Biology, Mount Sinai School of Medicine
Sarah Bacus, Ph.D., CSO & Senior Vice President, Innovation, Quintiles Pacific, Inc.
Sarah S. Bacus, Ph.D., CSO & Senior Vice President, Innovation, Quintiles Pacific, Inc
Serguei Kozlov, Ph.D., Principal Scientist, Center for Advanced Pre-Clinical Research, SAIC-Frederick, Inc.
Serguei Liachenko, Ph.D., Director, Bio-Imaging, National Center for Toxicological Research, Food and Drug Administration
Sonal S. Das, Ph.D., Associate Director, Research Programs, The Michael J. Fox Foundation for Parkinson’s Research
Sonia Poli, Ph.D., Head, Non-Clinical Development, Addex Pharma
Stephane Dhalluin, Ph.D., Director, Investigative Non-Clinical Safety, UCB Pharma
Stephen Salloway, M.D., M.S., Director, Neurology and the Memory and Aging Program, Butler Hospital; Professor, Clinical Neurosciences and Psychiatry, The Warren Alpert Medical School of Brown University
Steve McGaraughty, Ph.D., Head, Electrophysiology, Abbott Labs
Steven Andrews, Ph.D., Associate Director, Drug Discovery, Medicinal Chemistry, Array BioPharma
Steven Braithwaite, Ph.D., Senior Vice President, Drug Discovery, Neuroscience, Signum Biosciences
Steven E. Harte, Ph.D., Chronic Pain and Fatigue Research Center, Departments of Anesthesiology and Internal Medicine/Rheumatology, University of Michigan Medical School
Susan E. Browne, Ph.D., Director, Neuropharmacology, Merck Research Labs
Susan Kane, Ph.D., Professor, Tumor Cell Biology, City of Hope
Taleen Hanania, Ph.D., Vice President, Behavioral Pharmacology, PsychoGenics Inc.
Terry A. Van Dyke, Ph.D., Head, Mouse Cancer Genetics Program; Program Director, Cancer Pathways and Mechanisms, National Cancer Institute
Thomas B. Broudy, Ph.D., CSO, Molecular Response
Thomas Bocan, Ph.D., Senior Director, Pre-Clinical Imaging, Pharmatherapeutics Precision Medicine, Worldwide Research & Development, Pfizer, Inc.
Thomas Bocan, Ph.D., Senior Director, Pre-Clinical Imaging, Pharmatherapeutics, Precision Medicine, Worldwide Research & Development, Pfizer, Inc.
Tomas Guilarte, Ph.D., Leon Hess Professor & Chairman, Department of Environmental Health Sciences, Mailman School of Public Health, Columbia University
Valerie Morisset, Ph.D., Head, Electrophysiology, Convergence Pharmaceuticals
Virginia C. Moser, Ph.D., D.A.B.T., Toxicity Assessment Division, U.S. Environmental Protection Agency
Wanli W. Smith, M.D., Ph.D., Assistant Professor, Head, Molecular Neuroscience Laboratory, Pharmaceutical Sciences, University of Maryland School of Pharmacy
Warren Hirst, Ph.D., Associate Research Fellow, Neurodegeneration, Pfizer
William Salminen, Ph.D., DABT, Director, Center for Hepatotoxicity, National Center for Toxicological Research, Food and Drug Administration
Y. Paul Goldberg, M.B., Ch.B., Ph.D., FRCPC, Vice-President, Clinical Development, Xenon Pharmaceuticals, Inc.
Yvonne Will, Ph.D., Associate Research Fellow, Compound Safety Prediction, Pfizer Global R&D

5 Jun - 7 Jun 2012
United States of America
meeting website